Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05702034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Study acronym: LIBREXIA-STROK
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 54 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Site details revised at 42 of 880 sites Show 1 more changeShow less
    • Site details revised at 42 of 880 sites
  2. Completion moved earlier from Dec 9, 2026 to Oct 15, 2026 Enrollment target: 12532 to 12523 · Primary completion date: Nov 11, 2026 to Oct 15, 2026v53 Show 2 more changesShow less
    • Enrollment target: 12532 to 12523
    • Primary completion date: Nov 11, 2026 to Oct 15, 2026
  3. Site details revised at 1 of 880 sitesv52
  4. Re-verified, no change to tracked fieldsv51
  5. Site details revised at 1 of 880 sitesv50
  6. Trial status changed: Recruiting → Active, Not Recruiting Enrollment reduced: 15000 → 12532 participants · Study sites revised (880)v49 Show 2 more changesShow less
    • Enrollment reduced: 15000 → 12532 participants
    • Study sites revised (880)

    See this version in full on ClinicalTrials.gov ↗

  7. Trial sites expanded: 874 → 880 locationsv48
  8. Study sites: 873 to 874v47
  9. Study sites: 871 to 873v46
  10. Study sites: 870 to 871v45
  11. Study sites: 869 to 870v44
  12. Study sites: 863 to 869v43
  13. Study sites: 861 to 863v42
  14. Study sites: 856 to 861v41
  15. Study sites: 854 to 856v40
  16. Study sites: 849 to 854v39
  17. Re-verified, no change to tracked fieldsv38
  18. Study sites: 843 to 849v37
  19. Re-verified, no change to tracked fieldsv36
  20. Study sites: 833 to 843v35
  21. Study sites: 827 to 833v34
  22. Study sites: 823 to 827v33
  23. Study sites: 820 to 823v32
  24. Study sites: 813 to 820v31
  25. Re-verified, no change to tracked fieldsv30
  26. Study sites: 801 to 813v29
  27. Re-verified, no change to tracked fieldsv28
  28. Study sites: 783 to 801v27
  29. Re-verified, no change to tracked fieldsv26
  30. Study sites: 772 to 783v25
  31. Study sites: 764 to 772v24
  32. Study sites: 744 to 764v23
  33. Study sites: 725 to 744v22
  34. Study sites: 705 to 725v21
  35. Study sites: 679 to 705v20
  36. Study sites: 647 to 679v19
  37. Study sites: 612 to 647v18
  38. Study sites: 588 to 612v17
  39. Study sites: 548 to 588v16
  40. Study sites: 485 to 548v15
  41. Study sites: 427 to 485v14
  42. Study sites: 320 to 427v13
  43. Study sites: 269 to 320v12
  44. Study sites: 91 to 269v11
  45. Study sites: 63 to 91v10
  46. Study sites: 33 to 63v9
  47. Study sites: 22 to 33v8
  48. Study sites: 14 to 22 Completion date: Dec 31, 2026 to Dec 9, 2026v7 Show 1 more changeShow less
    • Completion date: Dec 31, 2026 to Dec 9, 2026
  49. Study sites: 11 to 14v6
  50. Study sites: 10 to 11 Completion date: Feb 26, 2027 to Dec 31, 2026v5 Show 1 more changeShow less
    • Completion date: Feb 26, 2027 to Dec 31, 2026
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Johnson & Johnson
289 trials monitored
See 17 trials at risk
Stroke
3,289 trials monitored
See 141 trials at risk
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Trial Details
NCT Number NCT05702034
Lead Sponsor Janssen Research & Development, LLC
Collaborators: Bristol Myers Squibb Company (BMS)
Conditions Ischemic Stroke; Ischemic Attack, Transient
Enrollment 12,523 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov